LANGUAGE:
LANGUAGE:
Our people are our pride, helping companies resonate with their customers for 20+ years.
We create, transform, test, and train more content than anyone in the world – from text, voice, audio, video, to structured & unstructured data.
Solutions
Our experts know the in-and-outs of your industry & its challenges.
Harness the Lionbridge Lainguage Cloud to support your end-to-end localization and content lifecycle
Our people are our pride, helping companies resonate with their customers for 20+ years.
About Us
Key Facts
Leadership
Insights
News
Trust Center
We create, transform, test, and train more content than anyone in the world – from text, voice, audio, video, to structured & unstructured data.
Content Services
Technical Writing
Training & eLearning
Financial Reports
Multicultural Marketing
Digital Experience Assessments
Translation Services
Translation
Video Localization
Software Localization
Website Localization
Translation for Regulated Companies
Interpretation
Multilingual SEO & Digital Marketing
Content Optimization
Testing Services
Functional QA & Testing
Compatibility Testing
Interoperability Testing
Performance Testing
Accessibility Testing
UX/CX Testing
Solutions
Digital Marketing
Live Events
Machine Translation
Our Knowledge Hubs
Positive Patient Outcomes
Future of Localization
Innovation to Immunity
COVID-19 Resource Center
Disruption Series
Patient Engagement
Lionbridge Insights
Our experts know the in-and-outs of your industry & its challenges.
Life Sciences
Banking & Finance
Retail
E-Commerce
Games
Automotive
Consumer Packaged Goods
Technology
Industrial Manufacturing
Legal Services
Travel & Hospitality
Harness the Lionbridge Lainguage Cloud to support your end-to-end localization and content lifecycle
Lainguage Cloud™ Platform
Connectivity
Translation Community
Workflow Technology
Smairt Content™
Smairt MT™
Smairt Data™
Language Quality
Analytics
SELECT LANGUAGE:
This is the third piece in the Lionbridge Disruption Series, a collection of commentary from life sciences experts on how the industry is changing as a result of the COVID-19 crisis.
The ongoing COVID-19 pandemic is impacting virtually every aspect of the business world, with especially tough impacts on the travel and hospitality sectors and small businesses. Meanwhile, the pharma sector faces a sudden increase in demand as the public looks to them for treatments, cures and vaccines. To manage this social responsibility despite the pandemic’s interruption of pharma’s research and development processes, the pharma sector needs to modify its approach to clinical trial execution.
On March 26, DIA moderated a panel discussion of experts from China who represented the full spectrum of the clinical trial process. Participants shared their findings on the impact that the coronavirus pandemic in China had on clinical trials being conducted there. As one would expect, the disruption to clinical trials was significant. Approximately 70% of ongoing trials were suspended or stalled during the height of the outbreak in China.
Within trials that continued throughout the outbreak, approximately 80% of study participants declined to travel to study sites, even if the government granted them an exception to any quarantine transportation restrictions.
This major disruption is driving the need for Business Continuity Plans (BCPs) that address clinical trial conduct under a pandemic and include specific action plans down to site and patient level. An essential part of such BCPs is a communication plan to ensure investigators, trial participants, CROs and monitors are clear on any protocol changes being implemented.
With the coronavirus pandemic now affecting over 180 countries around the globe, the potential disruption to the clinical trial process is massive. At the same time, the market need for those medications and treatments is greater than ever before. Sponsors of delayed trials find themselves using multi-channel communications in order to engage patients and hopefully minimize dropout.
While the global scale of the pandemic may make it impossible to activate sites in alternate locations in order to avoid suspending a study, the use of tools such as video, telephone outreach, social media marketing, web marketing and newsletters that can keep participants engaged and informed during the pandemic, and thus more likely to re-engage. Patient-facing digital technologies and the use of multi-media channels continue to play an increasingly important role in the execution of clinical trials, and in a crisis such as COVID-19 the value of such technologies become clear.
There are multiple benefits of virtual or hybrid trial designs that utilize technology for remote trial conduct, but a key advantage to using technologies is improved patient recruitment and retention. Technology enables regular patient interaction where patients are otherwise hard to reach.
The timeline and complexity of clinical trials is a barrier to patient participants in the best of times. With increased stress from the current pandemic, it’s critical that sponsors communicate effectively with participants. This means using plain language in the reader’s first language.
As new trials to fight and prevent COVID-19 start up on an accelerated timeline, regulatory agencies are encouraging international partnerships. To recruit the greatest number of participants, sponsors need to be prepared to translate into language outside their usual audience.
This is where Lionbridge Life Sciences excels. With decades of experience in remote-based translation and interpretation, we can help expand your recruitment pool in any part of the world at any time of day. We offer a speedy on-boarding process, skilled project managers and teams intimately familiar with the life sciences field in a variety of regulatory regions. Reach out and let us help you help the global community.